SCHEMBL2885747

SCHEMBL2885747

Cc1ccc(S(=O)(=O)n2cc(F)c3c(Cl)ccnc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
HSD11B1 P28845 2/20 0.40
HTT P42858 3/20 0.39
POLB P06746 2/20 0.39
ALDH3A1 P30838 1/20 0.39
NOD1 Q9Y239 1/20 0.39
TP53 P04637 2/20 0.39
ALDH1A1 P00352 3/20 0.38
PKM P14618 2/20 0.38
KDM4E B2RXH2 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
HTR6 P50406 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2888387 0.87 L3MBTL1 (0.48) L3MBTL1HSD11B1HTTPOLBALDH3A1
SCHEMBL16023204 0.85 L3MBTL1 (0.43) L3MBTL1HSD11B1HTTPOLBALDH3A1
SCHEMBL25278649 0.85 CA1 (0.47) L3MBTL1HSD11B1HTTPOLBALDH3A1
SCHEMBL2881500 0.85 L3MBTL1 (0.46) L3MBTL1HSD11B1HTTPOLBALDH3A1
SCHEMBL16023210 0.85 CA1 (0.47) L3MBTL1HSD11B1HTTPOLBALDH3A1
SCHEMBL30668758 0.85 L3MBTL1 (0.46) L3MBTL1HSD11B1HTTPOLBALDH3A1
SCHEMBL2889914 0.84 HSD11B1 (0.45) L3MBTL1HSD11B1HTTPOLBALDH3A1
SCHEMBL16967783 0.84 KDM4E (0.51) L3MBTL1HSD11B1HTTPOLBALDH3A1
SCHEMBL15805323 0.83 L3MBTL1 (0.39) L3MBTL1HSD11B1HTTTP53ALDH1A1
SCHEMBL15805465 0.83 ALDH1A1 (0.41) L3MBTL1HSD11B1HTTPOLBALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 L3MBTL1 1807/4885HSD11B1 4240/4885HTT 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.